/
Tumour Analysis-Lynch Syndrome Tumour Analysis-Lynch Syndrome

Tumour Analysis-Lynch Syndrome - PowerPoint Presentation

olivia-moreira
olivia-moreira . @olivia-moreira
Follow
429 views
Uploaded On 2016-05-26

Tumour Analysis-Lynch Syndrome - PPT Presentation

Dr Alan Donaldson Consultant in Clinical Genetics Bristol Why do tumour analysis To identify 15 of individuals whose colon cancer may be due to Lynch syndrome for DNA analysis 15 of colon cancers are MSI high ID: 335730

colon cancers mismatch mlh1 cancers colon mlh1 mismatch repair tumour msh6 msi ihc hnpcc syndrome lynch analysis colorectal tissue related instability msh2

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Tumour Analysis-Lynch Syndrome" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Tumour Analysis-Lynch Syndrome

Dr Alan Donaldson

Consultant

in Clinical Genetics

BristolSlide2

Why do tumour analysis?

To identify 1-5% of individuals whose colon cancer may be due to Lynch syndrome, for DNA analysis.

~15% of colon cancers are MSI high.

Generally have a better outcome.

Poorer response to 5 Fluorouracil?Slide3

Lynch Syndrome.

Hereditary non polyposis colorectal cancer – HNPCC.

Autosomal Dominant disorder.

Due to mutations in one of the mismatch repair genes.

MSH2 50%

MLH1 40%

MSH6 ~7%

PMS2 <5%

(TACSD1) ~1-2%

Accounts for 1-5% of all colon cancers.Slide4

Mismatch repair function.

MSH6 MSH2 MSH3

TTT TTTT TTT TTTTT

TTTTTTTT TTTTTTTTTTTTTT

PMS2 MLH1

HmutS

HmutS

HmutL

PMS1

MLH3

?Slide5

Amsterdam Criteria

Three or more family members, one of whom is a first degree relative of the other two, with HNPCC-related cancers*. 

Two successive affected generations.

One or more of the HNPCC-related cancers diagnosed before age 50 years.

Exclusion of (FAP).

* Colon, endometrial, small intestine, hepatobiliary, urinary tract.Slide6

Immunohistochemical (IHC) staining of the mismatch repair proteins.

MLH1 PMS2

MSH2 MSH6Slide7

Microsatellite instability (MSI) 1.Slide8

Normal tissue

Tumour tissue

Arrows indicated additional peaks

and microsatellite instability.Slide9

Sporadic loss of MLH1.

10-15% of all colorectal cancers.

Associated with DNA methylation.

Associated with BrafV600E in colonic tumours, but not endometrial.Slide10

Advantages / disadvantages of MSI.

Advantages.

Better sensitivity & Specificity than IHC.

Able to detect BRAFV600E mutations.

Disadvantages.

More expensive than IHC.

Doesn’t tell you what gene is involved. Slide11

Who is ordering these tests?

Genetics

Dermatology

Oncology

Gynaecology

Surgery?

Pathology?Slide12
Slide13

Any Questions?